Top 5 Most-Read Psoriasis Content of 2025

Each year, certain developments in psoriasis care and research rise to the top, capturing the attention of dermatologists, researchers, and patients alike. In 2025, AJMC.com readers gravitated toward studies revealing new systemic and topical therapies, links between environmental exposures and disease onset, and emerging comorbidity risks.

Here are the top 5 most-read psoriasis content of 2025.

5. FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis

The FDA approval of roflumilast (Zoryve; Arcutis Biotherapeutics) topical foam 0.3% gave patients with plaque psoriasis a new, steroid-free option particularly well suited for hair-bearing areas such as the scalp. Clinical trials demonstrated notable improvements in both symptom relief and clearance across affected regions, supporting its utility for patients seeking a once-daily, nonsteroidal topical therapy. This milestone highlights the expanding role of phosphodiesterase 4 (PDE-4) inhibition in dermatology and marks an important addition to the growing roster of steroid-sparing psoriasis treatments.

Read the full article.

4. Oral Roflumilast Shows Promise for Moderate to Severe Psoriasis

Interest in PDE-4 inhibition extended to systemic therapy, as emerging data showed encouraging outcomes with oral roflumilast in adults with moderate to severe psoriasis. Patients in the study experienced meaningful reductions in disease severity, accompanied by a favorable safety profile. Although further research is needed, the results suggest the potential for an oral, nonbiologic option that could fill the gap between topical therapies and biologic agents. For patients seeking alternatives to injectable treatments, these findings signal an important step forward.

Read the full article.

3. Air Pollution, Genes Together Raise Psoriasis Risk, Study Finds

Researchers examined how environmental exposures can combine with genetic susceptibility to influence disease risk in this study. This analysis found that individuals with a genetic predisposition to psoriasis faced an even higher likelihood of developing the condition when exposed to elevated levels of air pollutants. By identifying a synergistic relationship between pollution and inherited risk, the findings underscored the importance of evaluating psoriasis through a broader public health lens. The study also highlighted emerging opportunities for risk-stratified prevention.

Read the full article.

2. Bimekizumab, Brodalumab Safe, Effective Up to 36 Weeks for Psoriasis

Real-world data on the IL-17 inhibitors bimekizumab and brodalumab offered new insight into how these therapies perform outside controlled clinical trials. Over a 36-week period, both agents were shown to be effective in improving psoriasis severity, with acceptable safety across the patient population studied. Bimekizumab demonstrated somewhat higher measures of skin clearance in the analysis, but each biologic contributed significant clinical benefit. As demand grows for comparative evidence in psoriasis care, these findings provide valuable context for treatment decisions involving IL-17 inhibitors.

Read the full article.

1. Psoriasis Linked to Risk of Sjögren Syndrome, Study Finds

The most-read article of the year sheds light on the autoimmune connections between psoriasis and Sjögren syndrome. The study reported a higher incidence of Sjögren syndrome among individuals with psoriasis, with risk appearing even greater for those with psoriatic arthritis or those treated with biologics. Transcriptomic analyses pointed to shared immune pathways that may explain the overlap between the conditions. These insights reinforce the importance of monitoring for comorbid autoimmune diseases and support the growing recognition of psoriasis as a systemic inflammatory disorder rather than a condition limited to the skin.

Read the full article.